cGMP: Transition from bench to bedside: A report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Linda S. Hoffmann, Horng Haur Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Essential physiological homeostatic processes such as vascular tone, fluid balance, cardiorenal function, and sensory processes are regulated by the second messenger cyclic guanosine 3′, 5′-monophosphate (cGMP). Dysregulation of cGMP-dependent pathways plays an important role in cardiovascular diseases such as hypertension, pulmonary hypertension, heart failure, or erectile dysfunction. Thus, the cGMP pathway consisting of the cGMP-generating guanylyl cyclases, protein kinases, and phosphodiesterases (PDE) has evolved to an important drug target and is the focus of a wide variety of research fields ranging from unraveling mechanisms on the molecular level to understanding the regulation of physiological and pathophysiological processes by cGMP. Based on the results from basic and preclinical research, therapeutic drugs have been developed which modulate the cGMP pathway and are investigated in clinical trials. Riociguat, a nitric oxide (NO)-independent soluble guanylyl cyclase stimulator; recombinant B-type natriuretic peptide (BNP); or recombinant atrial natriuretic peptide (ANP) and PDE5 inhibitors are cGMP-modulating drugs that are already available for the treatment of pulmonary hypertension, acute heart failure, and erectile dysfunction, respectively. The latest results from basic to clinical research on cGMP were presented on the 6th International Conference on cGMP in Erfurt, Germany, and are summarized in this article.

Original languageEnglish (US)
Pages (from-to)707-718
Number of pages12
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume387
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Guanosine Monophosphate
Physiological Phenomena
Therapeutics
Erectile Dysfunction
Pulmonary Hypertension
Heart Failure
Pharmaceutical Preparations
Therapeutic Human Experimentation
Phosphodiesterase 5 Inhibitors
Water-Electrolyte Balance
Guanylate Cyclase
Brain Natriuretic Peptide
Phosphoric Diester Hydrolases
Atrial Natriuretic Factor
Second Messenger Systems
Research
Protein Kinases
Germany
Blood Vessels
Nitric Oxide

Keywords

  • Cardiovascular diseases
  • cGMP
  • Nitric oxide
  • Particulate guanylyl cyclase
  • sGC stimulator
  • Soluble guanylyl cyclase

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

@article{1d6b68a2b6494b768f88716936c836ec,
title = "cGMP: Transition from bench to bedside: A report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications",
abstract = "Essential physiological homeostatic processes such as vascular tone, fluid balance, cardiorenal function, and sensory processes are regulated by the second messenger cyclic guanosine 3′, 5′-monophosphate (cGMP). Dysregulation of cGMP-dependent pathways plays an important role in cardiovascular diseases such as hypertension, pulmonary hypertension, heart failure, or erectile dysfunction. Thus, the cGMP pathway consisting of the cGMP-generating guanylyl cyclases, protein kinases, and phosphodiesterases (PDE) has evolved to an important drug target and is the focus of a wide variety of research fields ranging from unraveling mechanisms on the molecular level to understanding the regulation of physiological and pathophysiological processes by cGMP. Based on the results from basic and preclinical research, therapeutic drugs have been developed which modulate the cGMP pathway and are investigated in clinical trials. Riociguat, a nitric oxide (NO)-independent soluble guanylyl cyclase stimulator; recombinant B-type natriuretic peptide (BNP); or recombinant atrial natriuretic peptide (ANP) and PDE5 inhibitors are cGMP-modulating drugs that are already available for the treatment of pulmonary hypertension, acute heart failure, and erectile dysfunction, respectively. The latest results from basic to clinical research on cGMP were presented on the 6th International Conference on cGMP in Erfurt, Germany, and are summarized in this article.",
keywords = "Cardiovascular diseases, cGMP, Nitric oxide, Particulate guanylyl cyclase, sGC stimulator, Soluble guanylyl cyclase",
author = "Hoffmann, {Linda S.} and Chen, {Horng Haur}",
year = "2014",
doi = "10.1007/s00210-014-0999-8",
language = "English (US)",
volume = "387",
pages = "707--718",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - cGMP

T2 - Transition from bench to bedside: A report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications

AU - Hoffmann, Linda S.

AU - Chen, Horng Haur

PY - 2014

Y1 - 2014

N2 - Essential physiological homeostatic processes such as vascular tone, fluid balance, cardiorenal function, and sensory processes are regulated by the second messenger cyclic guanosine 3′, 5′-monophosphate (cGMP). Dysregulation of cGMP-dependent pathways plays an important role in cardiovascular diseases such as hypertension, pulmonary hypertension, heart failure, or erectile dysfunction. Thus, the cGMP pathway consisting of the cGMP-generating guanylyl cyclases, protein kinases, and phosphodiesterases (PDE) has evolved to an important drug target and is the focus of a wide variety of research fields ranging from unraveling mechanisms on the molecular level to understanding the regulation of physiological and pathophysiological processes by cGMP. Based on the results from basic and preclinical research, therapeutic drugs have been developed which modulate the cGMP pathway and are investigated in clinical trials. Riociguat, a nitric oxide (NO)-independent soluble guanylyl cyclase stimulator; recombinant B-type natriuretic peptide (BNP); or recombinant atrial natriuretic peptide (ANP) and PDE5 inhibitors are cGMP-modulating drugs that are already available for the treatment of pulmonary hypertension, acute heart failure, and erectile dysfunction, respectively. The latest results from basic to clinical research on cGMP were presented on the 6th International Conference on cGMP in Erfurt, Germany, and are summarized in this article.

AB - Essential physiological homeostatic processes such as vascular tone, fluid balance, cardiorenal function, and sensory processes are regulated by the second messenger cyclic guanosine 3′, 5′-monophosphate (cGMP). Dysregulation of cGMP-dependent pathways plays an important role in cardiovascular diseases such as hypertension, pulmonary hypertension, heart failure, or erectile dysfunction. Thus, the cGMP pathway consisting of the cGMP-generating guanylyl cyclases, protein kinases, and phosphodiesterases (PDE) has evolved to an important drug target and is the focus of a wide variety of research fields ranging from unraveling mechanisms on the molecular level to understanding the regulation of physiological and pathophysiological processes by cGMP. Based on the results from basic and preclinical research, therapeutic drugs have been developed which modulate the cGMP pathway and are investigated in clinical trials. Riociguat, a nitric oxide (NO)-independent soluble guanylyl cyclase stimulator; recombinant B-type natriuretic peptide (BNP); or recombinant atrial natriuretic peptide (ANP) and PDE5 inhibitors are cGMP-modulating drugs that are already available for the treatment of pulmonary hypertension, acute heart failure, and erectile dysfunction, respectively. The latest results from basic to clinical research on cGMP were presented on the 6th International Conference on cGMP in Erfurt, Germany, and are summarized in this article.

KW - Cardiovascular diseases

KW - cGMP

KW - Nitric oxide

KW - Particulate guanylyl cyclase

KW - sGC stimulator

KW - Soluble guanylyl cyclase

UR - http://www.scopus.com/inward/record.url?scp=84904326480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904326480&partnerID=8YFLogxK

U2 - 10.1007/s00210-014-0999-8

DO - 10.1007/s00210-014-0999-8

M3 - Article

C2 - 24927824

AN - SCOPUS:84904326480

VL - 387

SP - 707

EP - 718

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 8

ER -